[HTML][HTML] Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative …
A Argiris, M Ghebremichael, J Gilbert… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2013•ncbi.nlm.nih.gov
Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in
Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI
Homepage Main Content Main Navigation Search PMC Full-Text Archive Search in PMC
Advanced Search User Guide Journal List J Clin Oncol PMC3612594 Other Formats PDF (224K)
Actions Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other …
Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI
Homepage Main Content Main Navigation Search PMC Full-Text Archive Search in PMC
Advanced Search User Guide Journal List J Clin Oncol PMC3612594 Other Formats PDF (224K)
Actions Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other …
Abstract
Purpose
We hypothesized that the addition of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in squamous cell carcinoma of the head and neck (SCCHN).
ncbi.nlm.nih.gov
